Fang; Lawrence Y.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Fang; Lawrence Y..The latest application filed is for "compounds to treat alzheimer's disease".

Company Profile

0.9.13

Fang; Lawrence Y. - Foster City CA
Fang; Lawrence Y. - South San Francisco CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compounds to treat alzheimer's disease App 20090074746 - Fang; Lawrence Y. ; et al.	2009-03-19
Methods to Treat Alzheimer's Disease App 20080058336 - Hom; Roy ; et al.	2008-03-06
Compounds to treat Alzheimer's disease App 20070213407 - Fang; Lawrence Y. ; et al.	2007-09-13
Compounds to treat Alzheimer's disease Grant 7,214,715 - Beck , et al. May 8, 2	2007-05-08
Compounds to treat Alzheimer's disease App 20060276642 - Hom; Roy ; et al.	2006-12-07
Methods to treat alzheimer's disease Grant 7,119,085 - Hom , et al. October 10, 2	2006-10-10
Compounds for the treatment of Alzheimer's disease App 20060211860 - Fang; Lawrence Y. ; et al.	2006-09-21
Compounds to treat Alzheimer's disease Grant 7,034,182 - Fang , et al. April 25, 2	2006-04-25
Compounds to treat Alzheimer's disease Grant 7,030,239 - Hom , et al. April 18, 2	2006-04-18
Compounds to treat Alzheimer's disease App 20040214846 - Hom, Roy ; et al.	2004-10-28
N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds Grant 6,767,918 - Wu , et al. July 27, 2	2004-07-27
Compounds to treat Alzheimer's disease Grant 6,737,420 - Hom , et al. May 18, 2	2004-05-18
N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds Grant 6,642,261 - Wu , et al. November 4, 2	2003-11-04
N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds App 20030191119 - Wu, Jing ; et al.	2003-10-09
Compounds to treat alzheimer's disease App 20030096864 - Fang, Lawrence Y. ; et al.	2003-05-22
N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds App 20020137743 - Wu, Jing ; et al.	2002-09-26
Compounds to treat alzheimer's disease App 20020128255 - Beck, James P. ; et al.	2002-09-12
Compounds to treat alzheimer's disease App 20020022623 - Hom, Roy ; et al.	2002-02-21
Methods to treat alzheimer's disease App 20020019403 - Hom, Roy ; et al.	2002-02-14
Compounds to treat alzheimer's disease App 20020016320 - Fang, Lawrence Y. ; et al.	2002-02-07
N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use Grant 6,117,901 - Wu , et al. September 12, 2	2000-09-12
Substituted 3-indolyl-5-pyrazolone compounds Grant 5,484,940 - Grant , et al. January 16, 1	1996-01-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.